Estradiol Valerate

Low Testosterone, hypoestrogenism, Fracture + 25 more

Treatment

3 FDA approvals

20 Active Studies for Estradiol Valerate

What is Estradiol Valerate

Estradiol valerate

The Generic name of this drug

Treatment Summary

Estradiol Valerate (E2V) is a modified form of the hormone estradiol, which is found naturally in the human body. It is used to treat menopausal symptoms such as hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. It is also used to treat some types of prostate cancer and can be found in combination with progestin as Natazia to prevent pregnancy and treat heavy menstrual bleeding. Estradiol Valerate is available as an injection called Delestrogen and is more potent than other forms of estrogen.

Delestrogen

is the brand name

image of different drug pills on a surface

Estradiol Valerate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Delestrogen

Estradiol valerate

1954

22

Approved as Treatment by the FDA

Estradiol valerate, also called Delestrogen, is approved by the FDA for 3 uses like Heavy Menstrual Bleeding and Oral Contraceptives .

Heavy Menstrual Bleeding

Used to treat Heavy Menstrual Bleeding in combination with Dienogest

Oral Contraceptives

Used to treat Oral Contraceptives in combination with Dienogest

Menorrhagia

Used to treat Heavy Menstrual Bleeding in combination with Dienogest

Effectiveness

How Estradiol Valerate Affects Patients

Estrogen is a hormone that acts on different areas of the body. It binds to two types of receptors: Estrogen Receptor Alpha and Estrogen Receptor Beta. It also activates the G Protein-coupled Estrogen Receptor, which is responsible for its effects in the body.

How Estradiol Valerate works in the body

Estradiol is a hormone that enters many cells in the body, including organs, breasts and the brain. When it binds to its target receptor, it can direct the cell to make proteins that express the effects of estradiol. These proteins can help to increase the production of other hormones, and reduce symptoms related to a lack of estradiol, like those experienced during menopause.

When to interrupt dosage

The recommended measure of Estradiol Valerate is contingent upon the diagnosed condition, including severe menopausal vulvovaginal atrophy, Menopausal Symptoms and Menorrhagia. The amount of dosage also depends on the method of administration featured in the table beneath.

Condition

Dosage

Administration

Menopausal Symptoms

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Low Testosterone

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Fracture

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

severe menopausal vulvovaginal atrophy

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Ovarian Resection

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Irregular Menstruation

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Oral Contraceptives

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Uterus

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Pharmaceutical Preparations

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Malignant neoplasm of prostate

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

moderate menopausal vulvovaginal atrophy

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Primary Ovarian Insufficiency

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Primary Amenorrhoea

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Hot flashes

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

hypoestrogenism

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

moderate Menopausal Vasomotor Symptoms

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Hormone Replacement Therapy

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Premature Menopause

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Menstruation Disturbances

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Osteoporosis, Postmenopausal

10.0 mg/mL, 20.0 mg/mL, 40.0 mg/mL, , 3.0 mg, 1.0 mg, 2.0 mg, 8.0 mg, 6.5 mg/mL

, Injection, Intramuscular, Injection - Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet - Oral, Liquid, Liquid - Intramuscular, Solution, Solution - Intramuscular, Kit, Oral, Tablet

Warnings

Estradiol Valerate has eleven contraindications, so it should not be taken in combination with the conditions described in the table below.

Estradiol Valerate Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Venous Thrombosis

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Pulmonary Embolism

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Metrorrhagia

Do Not Combine

Breast Cancer

Do Not Combine

Breast

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol Valerate may interact with Pulse Frequency

There are 20 known major drug interactions with Estradiol Valerate.

Common Estradiol Valerate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Estradiol valerate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Estradiol valerate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Estradiol valerate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Estradiol valerate.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol valerate.

image of a doctor in a lab doing drug, clinical research

Estradiol Valerate Novel Uses: Which Conditions Have a Clinical Trial Featuring Estradiol Valerate?

27 active clinical trials are currently examining the potential of Estradiol Valerate in ameliorating Irregular Menstruation, diminished reproductive organ function and female Castration.

Condition

Clinical Trials

Trial Phases

Low Testosterone

6 Actively Recruiting

Phase 4, Phase 2, Phase 1

Menopausal Symptoms

1 Actively Recruiting

Not Applicable

hypoestrogenism

1 Actively Recruiting

Phase 4

Hormone Replacement Therapy

0 Actively Recruiting

Fracture

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Menorrhagia

0 Actively Recruiting

Irregular Menstruation

0 Actively Recruiting

Primary Amenorrhoea

0 Actively Recruiting

Ovarian Resection

0 Actively Recruiting

Menopause

0 Actively Recruiting

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

female castration

0 Actively Recruiting

Uterus

0 Actively Recruiting

Malignant neoplasm of prostate

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Menstruation Disturbances

1 Actively Recruiting

Not Applicable

Amenorrhea

0 Actively Recruiting

Estradiol Valerate Reviews: What are patients saying about Estradiol Valerate?

5

Patient Review

10/17/2013

Estradiol Valerate for Low Estrogen After Operation to Remove Ovaries

I've used this treatment regularly for 52 years and it has kept me feeling healthy and alert. It also prevents the terrible headaches I used to get!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estradiol valerate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does estradiol valerate do to males?

"Estradiol valerate is sometimes used to treat advanced prostate cancer in men. The usual dosage is 30 mg or more every 1 to 2 weeks, given by intramuscular injection."

Answered by AI

Is estradiol valerate safe?

"However, it is one of the safest and most effective ways to treat symptoms of menopause.

Delestrogen (estradiol valerate injection) is safe to take; however, it may raise your risk of some serious medical problems when used for long periods of time. These problems include breast cancer and blood clots. Despite this, it is one of the safest and most effective ways to treat symptoms of menopause."

Answered by AI

What does estradiol valerate do in the body?

"This medication is designed to treat symptoms in women caused by a reduction of estrogen in the body. These symptoms include hot flashes and vaginal dryness, and are common during menopause. The medication works by replacing the estrogen in the body, and thus alleviating these symptoms."

Answered by AI

What is the difference between estradiol and estradiol valerate?

"Estradiol Valerate (also known as E2V) is a pro-drug ester of Estradiol. Estradiol is a naturally occurring hormone that circulates within the human body and is the most potent form of all estrogenic steroids. Estradiol acts as the major female sex hormone."

Answered by AI

Clinical Trials for Estradiol Valerate

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Menstrual Cycle vs. Birth Control Pills for Protein Metabolism

18 - 40
Female
Toronto, Canada

The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle. Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons. Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body. The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.

Recruiting
Has No Placebo

Goldring Center for High Performance Sport

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Estradiol Valerate clinical trials?

We made a collection of clinical trials featuring Estradiol Valerate, we think they might fit your search criteria.
Go to Trials

Have you considered Estradiol Valerate clinical trials?

We made a collection of clinical trials featuring Estradiol Valerate, we think they might fit your search criteria.
Go to Trials
Image of Rehabilitation R&D Service, Baltimore, MD in Baltimore, United States.

Cognitive Behavioral Therapy for Menopause

18+
Female
Baltimore, MD

Women are the fastest-growing group of U.S. Veterans. Over half of those using VA care are 45 or older, with more age-related health concerns than civilian women. The VA urgently needs gender-informed strategies to ensure women Veterans receive tailored care that addresses their intersecting mental, physical, and age related health concerns, as well as gender-linked stressors. One prominent example is menopause, a health transition period that, for many women, can be associated with negative physical and mental health concerns that can worsen their functioning and quality of life. This project will: (1) integrate stakeholder feedback to tailor Cognitive Behavioral Therapy for Menopause (CBT-Meno) for women Veterans with menopause concerns; and (2) refine and evaluate tailored CBT-Meno as a treatment to address these intersecting needs in a clinical trial.

Waitlist Available
Has No Placebo

Rehabilitation R&D Service, Baltimore, MD (+2 Sites)

Haley Miles-McLean, PhD

Image of Student Health and Wellness Building - Department of Kinesiology in Charlottesville, United States.

Nitrate Supplementation and Exercise for Menopause

45 - 75
Female
Charlottesville, VA

Menopause greatly increases cardiovascular disease risk (CVD). Current exercise guidelines are inadequate to ameliorate this risk and higher intensity exercise may be necessary for cardiovascular benefits in postmenopausal females. Oral nitrate supplementation enhances exercise performance and CVD risk profile in several clinical conditions. The investigators recently reported that 3-days of nitrate supplementation in postmenopausal females enhances acute post-exercise vascular function, in an intensity dependent manner. The effects of nitrate supplementation and exercise training over a longer training program remains unexplored. This investigation will examine the impact of exercise training intensity with and without inorganic nitrate supplementation, on CVD and fitness outcomes. Postmenopausal females will be tested for maximal oxygen uptake and lactate threshold before randomization to one of four groups: that inorganic nitrate-rich beetroot juice, or beetroot juice with nitrate extracted; and assigned to one-month of calorie matched high-intensity or moderate-intensity exercise training. Vascular function and fitness will be evaluated before and after training.

Recruiting
Paid Trial

Student Health and Wellness Building - Department of Kinesiology

Jason Allen, PhD

Have you considered Estradiol Valerate clinical trials?

We made a collection of clinical trials featuring Estradiol Valerate, we think they might fit your search criteria.
Go to Trials